Corcept Therapeutics Q2 EPS $0.25 Beats $0.15 Estimate, Sales $117.72M Beat $109.71M Estimate
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics reported Q2 earnings of $0.25 per share, beating the analyst consensus estimate of $0.15 by 66.67%. This is a 4.17% increase from the same period last year. The company also reported quarterly sales of $117.72 million, beating the analyst consensus estimate of $109.71 million by 7.30%. This is a 13.86% increase from the same period last year.
August 04, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics reported better than expected Q2 earnings and sales, which could positively impact its stock price.
Corcept Therapeutics reported Q2 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100